Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 May 7;23(6):62.
doi: 10.1007/s11886-021-01484-5.

Drug Repurposing: Claiming the Full Benefit from Drug Development

Eric Kort  1   2   3 , Stefan Jovinge  4   5   6
Affiliations
Review

Drug Repurposing: Claiming the Full Benefit from Drug Development

Eric Kort et al. Curr Cardiol Rep. .

Abstract

Purpose of review: Drug development has evolved over the years from being one-at-a-time to be massive screens in an industrial manner. Bringing a new therapeutic agent from concept to bedside can take a decade and cost billions of dollars-with most concepts failing along the way. Of the few compounds that make it to clinical testing, less than one out of eight make it to approval. This traditional drug development pipeline is challenging for prevalent diseases and makes the development of new therapeutics for rare diseases financially intractable.

Recent findings: Repurposing of drugs is an alternative to identify new applications for the thousands of compounds that have already been approved for clinical use. There is now a range of strategies for such efforts that leverage clinical data, pharmacologic data, and/or genomic or transcriptomic data. These strategies, together with examples, are detailed in this review. Drug repurposing bypasses the pre-clinical work and thereby opens up the opportunity to provide targeted treatment at a fraction of the cost that is accompanied with the development from ideation to full approval. Such an approach makes drug discovery for any disease process more efficient but holds particular promise for rare diseases for which there is little to no other viable drug development channel.

Keywords: Pharmacogenetics; Rare diseases; Repositioning; Repurposing.

PubMed Disclaimer

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
    1. DiMasi JA, Grabowski HG, Hansen RW. Innovation in the pharmaceutical industry: New estimates of R&D costs. J Health Econ. 2016;47:20–33. https://doi.org/10.1016/j.jhealeco.2016.01.012 . - DOI - PubMed
    1. Center” GI: FAQs about rare diseases. (2017). Accessed.
    1. FDA: FDA-Regulated Products and Facilities. https://www.fda.gov/about-fda/fda-basics/fact-sheet-fda-glance (2019). Accessed Nov 17 2020.
    1. Goldfarb ND. When patents became interesting in clinical research. Journal of Clinical Best Practices. 2006;2(3):1–3.
    1. Campillos M, Kuhn M, Gavin AC, Jensen LJ, Bork P. Drug target identification using side-effect similarity. Science. 2008;321(5886):263–6. https://doi.org/10.1126/science.1158140 . - DOI - PubMed

LinkOut - more resources